Roflumilast cream adds a much-needed element of simplicity for psoriasis patients and their dermatologists.
At the Skin of Color Update meeting in New York City, Mona Shahriari, MD, FAAD, shares her thoughts on prescribing the recently-approved tapinarof (VTAMA) for plaque psoriasis.
Deucravacitinib offers new hope for those with moderate-to-severe plaque psoriasis.
Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.
Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.
A brief discussion on the unmet needs and ongoing challenges in the treatment of plaque psoriasis.
Shared insight on which factors are most important in determining second-line therapy for plaque psoriasis.
Moving on to the second patient case, panelists discuss switching therapy at treatment failure for plaque psoriasis.
Panelists share which factors they use to determine optimal therapy in the moderate to severe plaque psoriasis setting.